NVCT NUVECTIS PHARMA INC revenue, earnings and financials
For the quarter ended June 30, 2026, NUVECTIS PHARMA INC reported revenue of n/a, net income of −$7.02M and diluted EPS of −$0.30; for the fiscal year ended December 2025 revenue was n/a.
NVCT annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$27.6M, net income −$26.4M (margin n/a), EPS −$1.32
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$19.8M, net income −$19.0M (margin n/a), EPS −$1.11
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$22.9M, net income −$22.3M (margin n/a), EPS −$1.43
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$19.2M, net income −$19.1M (margin n/a), EPS −$1.51
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$12.9M, net income −$12.9M (margin n/a), EPS −$3.02
NVCT quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$7.02M, EPS −$0.30
- Quarter ended Mar 31, 2026: revenue n/a, net income −$6.05M, EPS −$0.26
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$7.31M, EPS −$0.31
- Quarter ended Sep 30, 2025: revenue n/a, net income −$7.46M, EPS −$0.44
- Quarter ended Jun 30, 2025: revenue n/a, net income −$6.33M, EPS −$0.30
- Quarter ended Mar 31, 2025: revenue n/a, net income −$5.33M, EPS −$0.27
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$6.25M, EPS −$0.36
- Quarter ended Sep 30, 2024: revenue n/a, net income −$4.15M, EPS −$0.24
- Quarter ended Jun 30, 2024: revenue n/a, net income −$4.43M, EPS −$0.26
- Quarter ended Mar 31, 2024: revenue n/a, net income −$4.17M, EPS −$0.25
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$6.62M, EPS −$0.41
- Quarter ended Sep 30, 2023: revenue n/a, net income −$5.88M, EPS −$0.37
- Quarter ended Jun 30, 2023: revenue n/a, net income −$5.71M, EPS −$0.38
- Quarter ended Mar 31, 2023: revenue n/a, net income −$4.05M, EPS −$0.27
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$6.70M, EPS −$0.49
- Quarter ended Sep 30, 2022: revenue n/a, net income −$5.88M, EPS −$0.42
- Quarter ended Jun 30, 2022: revenue n/a, net income −$3.57M, EPS −$0.28
- Quarter ended Mar 31, 2022: revenue n/a, net income −$2.94M, EPS −$0.32
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$2.26M, EPS −$0.56
- Quarter ended Sep 30, 2021: revenue n/a, net income −$4.67M, EPS −$1.04
NVCT cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$16.0M, share buybacks n/a, dividends $0.00 per share
- Fiscal year ended Dec 2024: operating cash flow −$12.2M, share buybacks n/a, dividends $0.00 per share
- Fiscal year ended Dec 2023: operating cash flow −$16.0M, share buybacks n/a, dividends $0.00 per share
- Fiscal year ended Dec 2022: operating cash flow −$13.6M, share buybacks n/a, dividends $0.00 per share
- Fiscal year ended Dec 2021: operating cash flow −$9.50M, share buybacks n/a
NVCT balance sheet
- Jun 30, 2026: cash $22.2M, total assets $22.4M, total liabilities $13.3M, shareholders' equity $9.08M
- Mar 31, 2026: cash $25.1M, total assets $25.4M, total liabilities $11.2M, shareholders' equity $14.2M
- Dec 31, 2025: cash $31.6M, total assets $31.7M, total liabilities $13.3M, shareholders' equity $18.4M
- Sep 30, 2025: cash $35.4M, total assets $35.6M, total liabilities $11.6M, shareholders' equity $24.0M
- Jun 30, 2025: cash $26.8M, total assets $27.0M, total liabilities $10.1M, shareholders' equity $16.9M
- Mar 31, 2025: cash $29.9M, total assets $30.1M, total liabilities $9.19M, shareholders' equity $21.0M
- Dec 31, 2024: cash $18.5M, total assets $18.6M, total liabilities $8.89M, shareholders' equity $9.71M
- Sep 30, 2024: cash $17.2M, total assets $17.3M, total liabilities $6.32M, shareholders' equity $11.0M
Is NVCT profitable?
No. NUVECTIS PHARMA INC lost $27.8M over the last four quarters.
What is NVCT's EPS?
Diluted earnings per share over the last four quarters were −$1.31; −$0.30 in the latest quarter.